Isabelle Laure Ray-Coquard

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi et al. · The Lancet Oncology · 2011 · 239 citations

Medicine, Oncology, Neoplasia +5

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

Jean‐Yves Blay, Nicolas Penel, Isabelle Laure Ray-Coquard et al. · Journal of Clinical Oncology · 2021 · 29 citations

Medicine, Oncology, Pharmacotherapy +15

Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study

Antoîne Italiano, Nicolas Penel, Maud Toulmonde et al. · Annals of Oncology · 2018 · 17 citations · Full text

Medicine, Oncology, Pharmacology +16

1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

Jean‐Yves Blay, Sylvie Chevret, Nicolas Penel et al. · Annals of Oncology · 2020 · 14 citations

Medicine, Oncology, Pharmacology +13